G-CSF- and erythropoietin-based cell therapy: a promising strategy for angiomyogenesis in myocardial infarction

References

• Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infracted myocardium. Nature410, 701–705 (2001).
   PubMed Web of Science ®Google Scholar
• Kocher AA, Schuster MD, Szabolcs MJ et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med.7, 430–436 (2001).
   PubMed Web of Science ®Google Scholar
• Orlic D, Kajstura J, Chimenti S et al. Mobilized bone marrow cells repair the infracted heart, improving function and survival. Proc. Natl Acad. Sci. USA98, 10344–10349 (2001).
   PubMed Web of Science ®Google Scholar
• Hill JM, Syed MA, Arai AE et al. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J. Am. Coll. Cardiol.46(9), 1643–1648 (2005).
   PubMed Web of Science ®Google Scholar
• Kawada H, Fujita J, Kinjo K et al. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood104, 3581–1587 (2004).
   PubMed Web of Science ®Google Scholar
• Ripa RS, Haack-Sørensen M, Wang Y et al. Bone marrow derived mesenchymal cell mobilization by granulocyte-colony stimulating factor after acute myocardial infarction: results from the Stem Cells in Myocardial Infarction (STEMMI) trial. Circulation116, I-24–I-30 (2007).
   Google Scholar
• Sato T, Suzuki H, Kusuyama T et al. G-CSF after myocardial infarction accelerates angiogenesis and reduces fibrosis in swine. Int. J. Cardiol. DOI: 17692407 (2007) (Epub ahead of print).
   Google Scholar
• Ohtsuka M, Takano H, Zou Y et al. Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization. FASEB J.18, 851–853 (2004).
   PubMed Web of Science ®Google Scholar
• Balsam LB, Wagers AJ, Christensen JL et al. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature428, 668–673 (2004).
   PubMed Web of Science ®Google Scholar
• Murry CE, Soonpaa MH, Reinecke H et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature428, 664–668 (2004).
   PubMed Web of Science ®Google Scholar
• Powell TM, Paul JD, Hill JM et al. Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol.25(2), 296–301 (2005).
   PubMed Web of Science ®Google Scholar
• Honold J, Lehmann R, Heeschen C et al. Effects of granulocyte colony simulating factor on functional activities of endothelial progenitor cells in patients with chronic ischemic heart disease. Arterioscler. Thromb. Vasc. Biol.26(10), 2238–2243 (2006).
   PubMed Web of Science ®Google Scholar
• Britten MB, Abolmaali ND, Assmus B et al. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation108, 2212–2218 (2003).
   PubMed Web of Science ®Google Scholar
• Heeschen C, Lehmann R, Honold J et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation109, 1615–1622 (2004).
   PubMed Web of Science ®Google Scholar
• Assmus B, Urbich C, Aicher A et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ. Res.92, 1049–1055 (2003).
   PubMed Web of Science ®Google Scholar
• Spyridopoulos I, Haendeler J, Urbich C et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation110, 3136–3142 (2004).
   PubMed Web of Science ®Google Scholar
• Dawn B, Guo YR, Rezazadeh A et al. Postinfarct cytokine therapy regenerates cardiac tissue and improves left ventricular function. Circ. Res.98, 1098–1105 (2006).
   PubMed Web of Science ®Google Scholar
• Urbich C, Aicher A, Heeschen C et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J. Mol. Cell. Cardiol.39, 733–742 (2005).
   PubMed Web of Science ®Google Scholar
• Rehman J, Li J, Orschell CM et al. Peripheral blood ‘endothelial progenitor cells’ are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation107, 1164–1169 (2003).
   PubMed Web of Science ®Google Scholar
• Kinnaird T, Stabile E, Burnett MS et al. Bone marrow–derived cells for enhancing collateral development mechanisms, animal data, and initial clinical experiences. Circ. Res.95, 354–363 (2004).
   PubMed Web of Science ®Google Scholar
• Deindl E, Zaruba MM, Brunner S et al. G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis. FASEB J.20(7), 956–958 (2006).
   PubMed Web of Science ®Google Scholar
• Kuhlmann MT, Kirchhof P, Klocke R et al. G-CSF/SCF reduces inducible arrhythmias in the infarcted heart potentially via increased connexin43 expression and arteriogenesis. J. Exp. Med.203(1), 879–887 (2006).
   Google Scholar
• Buschmann IR, Hoefer IE, van Royen N et al. GM-CSF: a strong arteriogenic factor acting by amplification of monocyte function. Atherosclerosis159, 343–356 (2001).
   PubMed Web of Science ®Google Scholar
• Seiler C, Pohl T, Wustmann K et al. Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation23, 2012–2017 (2001).
   Google Scholar
• Ziegelhoeffer T, Fernandez B, Kostin S et al. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ. Res.94, 230–238 (2004).
   PubMed Web of Science ®Google Scholar
• Hattori K, Dias S, Heissig B et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp. Med.193, 1005–1014 (2001).
   PubMed Web of Science ®Google Scholar
• Silvestre JS, Mallat Z, Tedgui A et al. Post-ischaemic neovascularization and inflammation. Cardiovas. Res.78(2), 242–249 (2008).
   PubMed Web of Science ®Google Scholar
• Harada M, Qin Y, Takano H et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat. Med.11, 305–311 (2005).
   PubMed Web of Science ®Google Scholar
• Takano H, Ueda K, Hasegawa H et al. G-CSF therapy for acute myocardial infarction. Trends Pharmacol. Sci.28(10), 512–517 (2007).
   PubMed Web of Science ®Google Scholar
• Ueda K, Takano H, Hasegawa H et al. Granulocyte colony stimulating factor directly inhibits myocardial ischemia–reperfusion injury through Akt-endothelial NO synthase pathway. Arterioscler. Thromb. Vasc. Biol.26, e108–e113 (2006).
   PubMed Web of Science ®Google Scholar
• Sugano Y, Anzai T, Yoshikawa T et al. Granulocyte colony-stimulating factor attenuates early ventricular expansion after experimental myocardial infarction. Cardiovasc. Res.65, 446–456 (2005).
   PubMed Web of Science ®Google Scholar
• Minatoguchi S, Takemura G, Chen XH et al. Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. Circulation109, 2572–2580 (2004).
   PubMed Web of Science ®Google Scholar
• Misao Y, Takemura G, Arai M et al. Importance of recruitment of bone mrrow-derived CXCR4+ cells in post-infarct cardiac repair mediated by G-CSF. Cardio. Res.71, 455–465 (2006).
   PubMed Web of Science ®Google Scholar
• Kang HJ, Kim HS, Koo BK et al. Intracoronary infusion of the mobilized peripheral blood stem cell by G-CSF is better than mobilization alone by G-CSF for improvement of cardiac function and remodeling: 2-year follow-up results of the Myocardial Regeneration and Angiogenesis in Myocardial Infarction with G-CSF and Intra-Coronary Stem Cell Infusion (MAGIC Cell) 1 trial. Am. Heart J.153(2), 237e1–e8 (2007).
   Google Scholar
• Suzuki K, Nagashima K, Arai M et al. Effect of granulocyte colony-stimulating factor treatment at a low dose but for a long duration in patients with coronary heart disease. Circ. J.70, 430–437 (2006).
   PubMed Web of Science ®Google Scholar
• Takano H, Hasegawa H, Kuwabara Y et al. Feasibility and safety of granulocyte colony-stimulating factor treatment in patients with acute myocardial infarction. Int. J. Cardiol.122(1), 41–47 (2007).
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Rigolin GM, Cittaniti P et al. Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. Eur. Heart J.26, 1838–1845 (2005).
   PubMed Web of Science ®Google Scholar
• Ellis SG, Penn MS, Bolwell B et al. Granulocyte colony stimulating factor in patients with large acute myocardial infarction: Results of a pilot dose-escalation randomized trial. Am. Heart J.152, e91–e94 (2006).
   Google Scholar
• Ince H, Petzsch M, Kleine HD et al. Preservation from left ventricular remodeling by Front-Integrated Revascularization And Stem Cell Liberation In Evolving Acute Myocardial Infarction By Use Of Granulocyte Colony-stimulating Factor (FIRSTLINE-AMI). Circulation112(20), 3097–3106 (2005).
   PubMed Web of Science ®Google Scholar
• Ripa RS, Jørgensen E, Wang Y et al. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled Stem Cells in Myocardial Infarction (STEMMI) trial. Circulation113(16), 1983–1992 (2006).
   PubMed Web of Science ®Google Scholar
• Zohlnhöfer D, Ott I, Mehilli J et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA295(9), 1003–1010 (2006).
   PubMed Web of Science ®Google Scholar
• Engelmann MG, Theiss HD, Hennig-Theiss C et al. Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. J. Am. Coll. Cardiol.48(8), 1712–1721 (2006).
   PubMed Web of Science ®Google Scholar
• Leone AM, Galiuto L, Garramone B et al. Usefulness of granulocyte colony-stimulating factor in patients with a large anterior wall acute myocardial infarction to prevent left ventricular remodeling (the rigenera study). Am. J. Cardiol.100(3), 3974–3903 (2007).
   Google Scholar
• Lipinski MJ, Biondi-Zoccai GG, Abbate A et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J. Am. Coll. Cardiol.50(18), 1761–1767 (2007).
   PubMed Web of Science ®Google Scholar
• Kang HJ, Lee HY, Na SH et al. Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction: the MAGIC Cell-3-DES randomized, controlled trial. Circulation114(1 Suppl.), I145–I151 (2006).
   PubMed Web of Science ®Google Scholar
• Erbs S, Linke A, Adams V et al. Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: first randomized and placebo-controlled study. Circ. Res.97, 756–762 (2005).
   PubMed Web of Science ®Google Scholar
• Losordo DW, Schatz RA, White CJ et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a Phase I/IIa double-blind, randomized controlled trial. Circulation115(25), 3165–3172 (2007).
   PubMed Web of Science ®Google Scholar
• Kang WJ, Kang HJ, Kim HS et al. Tissue distribution of F-18 FDG labeled peripheral hematopoietic stem cell after intracoronary administration in patients with myocardial infarction. J. Nucl. Med.47, 1295–1301 (2006).
   PubMed Web of Science ®Google Scholar
• Haghighat A, Weiss D, Whalin MK et al. Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor exacerbate atherosclerosis in apolipoprotein E-deficient mice. Circulation115(15), 2049–2054 (2007).
   PubMed Web of Science ®Google Scholar
• Kang HJ, Kim YS, Koo BK et al. Effects of stem cell therapy with g-csf on coronary artery after drug-eluting stent implantation in patients with acute myocardial infarction. Heart94(5), 604–609 (2007).
   PubMed Web of Science ®Google Scholar
• Cho HJ, Kim TY, Cho HJ et al. The effect of stem cell mobilization by granulocyte-colony stimulating factor on neointimal hyperplasia and endothelial healing after vascular injury with bare-metal versus paclitaxel-eluting stents. J. Am. Coll. Cardiol.48, 366–374 (2006).
   PubMed Web of Science ®Google Scholar
• Kang HJ, Kim HS, Zhang SY et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet363, 751–756 (2004).
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Takano H, Ohtsuka M et al. G-CSF prevents the progression of atherosclerosis and neointimal formation in rabbits. Biochem. Biophys. Res. Commun.344(1), 370–376 (2006).
   PubMed Web of Science ®Google Scholar
• Anagnostou A, Liu Z, Steiner M et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl Acad. Sci. USA91, 3974–3978 (1994).
   PubMed Web of Science ®Google Scholar
• Tramontano AF, Muniyappa R, Black AD et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem. Biophys. Res. Commun.308, 990–994 (2003).
   PubMed Web of Science ®Google Scholar
• Brines M, Grasso G, Fiordaliso F et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl Acad. Sci. USA101, 14907–14912 (2004).
   PubMed Web of Science ®Google Scholar
• Anagnostou A, Lee ES, Kessimian N et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc. Natl Acad. Sci. USA87, 5978–5982 (1990).
   PubMed Web of Science ®Google Scholar
• Ribatti D, Presta M, Vacca A et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood93(8), 2627–2636 (1999).
   PubMed Web of Science ®Google Scholar
• Heeschen C, Aicher A, Lehmann R et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood102, 1340–1346 (2003).
   PubMed Web of Science ®Google Scholar
• Coleman T, Westenfelder C, Togel F et al. Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc. Natl Acad. Sci. USA103(15), 5965–5970 (2006).
   PubMed Web of Science ®Google Scholar
• Bahlmann FH, De Groot K, Spandau JM et al. Erythropoietin regulates endothelial progenitor cells. Blood103, 921–926 (2004).
   PubMed Web of Science ®Google Scholar
• Scholz D, Schaper W. Enhanced arteriogenesis in mice overexpressing erythropoietin. Cell Tissue Res.324(3), 395–401 (2006).
   PubMed Web of Science ®Google Scholar
• Leist M, Ghezzi P, Grasso G et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science305, 239–242 (2004).
   PubMed Web of Science ®Google Scholar
• Maiese K, Li F, Chong Z. New Avenues of Exploration for Erythropoietin. JAMA293, 90–95 (2005).
   PubMed Web of Science ®Google Scholar
• Cai Z, Semenza G. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation109, 2050–2053 (2004).
   PubMed Web of Science ®Google Scholar
• Ratajczak J, Majka M, Kijowski J et al. Biological significance of MAPK, AKT and JAK-STAT protein activation by various erythro poietic factors in normal human early erythroid cells. Br. J. Haematol.115, 195–204 (2001).
   PubMed Web of Science ®Google Scholar
• Brunet A, Bonni A, Zigmond MJ et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell96, 857–868 (1999).
   PubMed Web of Science ®Google Scholar
• Somervaille TC, Linch DC, Khwaja A. Growth factor withdrawal from primary human erythroid progenitors induces apoptosis through a pathway involving glycogen synthase kinase-3 and Bax. Blood98, 1374–1381 (2001).
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Kang JQ, Maiese K et al. Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J. Cereb. Blood Flow Metab.23, 320–330 (2003).
   PubMed Web of Science ®Google Scholar
• Rui T, Feng Q, Lei M et al. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc. Res.65, 719–727 (2005).
   PubMed Web of Science ®Google Scholar
• Wald M, Gutnisky A, Borda E et al. Erythropoietin modified the cardiac action of ouabain in chronically anaemic-uraemic rats. Nephron71, 190–196 (1995).
   PubMed Web of Science ®Google Scholar
• Porat O, Neumann D, Zamir O et al. Erythropoietin stimulates atrial natriuretic peptide secretion from adult rat cardiac atrium. J. Pharmacol. Exp. Ther.276, 116–128 (1996).
   PubMed Web of Science ®Google Scholar
• Lipšic E, Schoemaker R, van der Meer P et al. Protective effects of erythropoietin in cardiac ischemia from bench to bedside. J. Am. Coll. Cardiol.48, 216–217 (2006).
   Google Scholar
• Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat. Rev. Neurosci.6, 484–494 (2005).
   PubMed Web of Science ®Google Scholar
• Calvillo L, Latini R, Kajstura J et al. Recombinant human erythropoietin protects the myocardium from ischemia–reperfusion injury and promotes beneficial remodeling. Proc. Natl Acad. Sci. USA100(8), 4802–4806 (2003).
   PubMed Web of Science ®Google Scholar
• Lipsic E, van der Meer P, Henning RH et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J. Cardiovasc. Pharmacol.44, 473–479 (2004).
   PubMed Web of Science ®Google Scholar
• Parsa CJ, Matsumoto A, Kim J et al. A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest.112, 999–1007 (2003).
   PubMed Web of Science ®Google Scholar
• van der Meer P, Lipsic E, Henning RH et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J. Am. Coll. Cardiol.46, 125–133 (2005).
   PubMed Web of Science ®Google Scholar
• Hirata A, Minamino T, Asanuma H et al. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc. Drugs Ther.19, 33–40 (2005).
   PubMed Web of Science ®Google Scholar
• McMahon LP, Mason K, Skinner SL et al. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol. Dial. Transplant15, 142–150 (2000).
   Google Scholar
• Silverberg DS, Wexler D, Sheps D et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J. Am. Coll. Cardiol.37(7), 1775–1780 (2001).
   PubMed Web of Science ®Google Scholar
• Mancini DM, Katz SD, Lang CC et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation107, 294–299 (2003).
   PubMed Web of Science ®Google Scholar
• Namiuchi S, Kagaya Y, Ohta J et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J. Am. Coll. Cardiol.45, 1406–1412 (2005).
   PubMed Web of Science ®Google Scholar
• van der Meer P, Voors AA, Lipsic E et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J. Am. Coll. Cardiol.44, 636–637 (2004).
   Google Scholar
• Ferrario M, Massa M, Rosti V et al. Early haemoglobin-independent increase of plasma erythropoietin levels in patients with acute myocardial infarction. Eur. Heart J.1805–1813 (2007).
   PubMed Web of Science ®Google Scholar
• Lipsic E, van der Meer P, Voors AA et al. A single bolus of a long-acting erythropoietin analogue darbepoetin a in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc. Drugs Ther.20, 135–141 (2006).
   PubMed Web of Science ®Google Scholar
• Akimoto T, Kusano E, Inaba T et al. Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int.58, 269–282 (2000).
   PubMed Web of Science ®Google Scholar
• Morakkabati N, Gollnick F, Meyer R et al. Erythropoietin induces Ca2+ mobilization and contraction in rat mesangial and aortic smooth muscle cultures. Exp. Hematol.24, 392–397 (1996).
   PubMed Web of Science ®Google Scholar
• Heidenreich S, Rahn KH, Zidek W et al. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int.39, 259–265 (1991).
   PubMed Web of Science ®Google Scholar
• Carlini R, Obialo CI. Rothstein M. Intravenous erythropoietin administration increases plasma endothelin and blood pressure in hemodialysis patients. Am. J. Hypertens.6, 103–107 (1993).
   PubMed Web of Science ®Google Scholar
• Henry DH, Bowers P, Romano MT et al. Epoetin alfa: clinical evolution of a pleiotropic cytokine. Arch. Intern. Med.164, 262–276 (2004).
   PubMedGoogle Scholar
• Tobu M, Iqbal O, Fareed D et al. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin. Appl. Thromb. Hemost.10, 225–232 (2004).
   PubMed Web of Science ®Google Scholar
• Stohlawetz PJ, Dzirlo L, Hergovich N et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood95(9), 2983–2989 (2000).
   PubMed Web of Science ®Google Scholar
• Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J. Natl Cancer Inst.98, 708–714 (2006).
   PubMed Web of Science ®Google Scholar
• Phrommintikul A, Haas SJ, Elsik M et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet369(9559), 381–388 (2007).
   PubMed Web of Science ®Google Scholar
• Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA299(8), 914–924 (2008).
   PubMed Web of Science ®Google Scholar
• Cotter DJ, Stefanik K, Zhang Y et al. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. J. Clin. Epidem.57, 1086–1095 (2004).
   PubMed Web of Science ®Google Scholar
• Tang Y, Rinder H, Katz S et al. Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: Results of a double-blind, placebo-controlled randomized trial. Am. Heart J.154(494) e14–e7 (2007).
   Google Scholar
• Yasuda Y, Fujita Y, Matsuo T et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis24, 1021–1029 (2003).
   PubMed Web of Science ®Google Scholar
• Henke M, Laszig R, Rübe C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet362(9392), 1255–1260 (2003).
   PubMed Web of Science ®Google Scholar
• Erbayraktar S, Grasso G, Sfacteria A et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl Acad. Sci. USA100, 6741–6746 (2003).
   PubMed Web of Science ®Google Scholar
• Fiordaliso F, Chimenti S, Staszewsky L et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia–reperfusion injury. Proc. Natl Acad. Sci. USA102, 2046–2051 (2005).
   PubMed Web of Science ®Google Scholar
• Moon C, Krawczyk M, Paik D et al. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J. Pharmacol. Exp. Ther.316, 999–1005 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhang F, Zhang Y et al. Combining erythropoietin infusion with intramyocardial delivery of bone marrow cells is more effective for cardiac repair. Transpl. Int.20(2), 174–183 (2007).
   PubMed Web of Science ®Google Scholar